Table 1 Clinical data of all patients included in the trial
Internal-controlled trial | Randomized controlled trial | |||
|---|---|---|---|---|
No.of patients | No. of patients | |||
99mTc-Rituximab | fTcSC | Significance | ||
Age (years) | ||||
≤ 50 | 16 | 22 | 23 | P = 0.467 |
> 50 | 9 | 19 | 27 | |
Breast type | ||||
dense breast | 12 | 22 | 24 | P = 0.591 |
non-dense breast | 13 | 19 | 26 | |
Tumor size (cm) | ||||
≤ 2 | 14 | 15 | 26 | P = 0.071 |
2 < R ≤ 5 | 11 | 23 | 24 | |
> 5 | 0 | 3 | 0 | |
Pathological type | ||||
ductal carcinoma in situ | 3 | 9 | 6 | P = 0.236 |
infiltrating ductal carcinoma | 21 | 28 | 41 | |
special type | 1 | 2 | 3 | |
mixed type | 0 | 2 | 0 | |
Tumor location | ||||
Left breast | 12 | 23 | 23 | P = 0.338 |
Right breast | 13 | 18 | 27 | |
Upper outer quadrant | 17 | 20 | 28 | P = 0.265 |
Lower outer quadrant | 2 | 7 | 8 | |
Upper inner quadrant | 4 | 8 | 9 | |
Lower inner quadrant | 2 | 6 | 2 | |
Center | 0 | 0 | 3 | |
Molecular type | ||||
Luminal A | 2 | 3 | 6 | P = 0.802 |
Luminal B | 11 | 20 | 27 | |
ERBB2+ | 6 | 5 | 6 | |
Basal-like | 5 | 8 | 8 | |
Deletion | 1 | 5 | 3 | |